|
In the wake of Covid-19, there is an increased focus on the importance of Life & Health Sciences. Hong Kong, as an international Innovation and Technology (I&T) hub, is instrumental in developing this sector to build a better future. Today, Hong Kong has become Asia’s largest biotech funding raising hub and is one of the most efficient cities offering top-tier healthcare services at affordable costs. Hong Kong provides a dynamic and data-centric healthcare system, excellence academic achievements, robust infrastructures to support R&D and clinical trials, and funding access from both government and private sectors to accelerate downstream commercialization. To gain an insight about our strengths and opportunities, and an update of key milestones achieved, you are cordially invited to join the webinar on Unlock the Life and Health Sciences Potential through Innovation.
|
|
|
|
|
10:00am-12:30pm (Hong Kong Time GMT+8)
|
|
|
|
- Highlight Hong Kong’s latest milestones in Life and Health Sciences, from upstream research and development to downstream commercialisation and business expansion
- Great lineup of speakers from the research area to the industrial area to share their developments, experiences, and innovations in Life and Health Sciences
|
|
|
|
|
We are thrilled to have Ms Lillian Cheong, JP, Under Secretary for Innovation, Technology and Industry to deliver the Opening Remarks. Professor Chan Wai-Yee, Pro Vice-Chancellor/ Vice-President (Strategic Development) and Li Ka Shing Professor of Biomedical Sciences, The Chinese University of Hong Kong will deliver a Keynote Speech on “Unlock the life and health science potential through innovation.
|
|
|
|
|
|
|
Ms Lillian Cheong, JP
|
|
Innovation, Technology and Industry Bureau
|
|
|
|
|
Prof Chan Wai-Yee
|
|
The Chinese University of Hong Kong
|
|
|
|
|
Dr Jimmy Chiang, acting Director-General of Investment Promotion from InvestHK and Mr Edward Au, Southern Region Managing Partner from Deloitte China will deliver Welcome Remarks. Followed by Mr Andy Wong, Head of Innovation and Technology from InvestHK to deliver a Report Highlight on Hong Kong’s life and health sciences market opportunities.
|
|
|
|
|
|
|
Dr Jimmy Chiang
|
|
Invest Hong Kong
|
|
|
|
|
Mr Edward Au
|
|
Deloitte China
|
|
|
|
|
Mr Andy Wong
|
|
Invest Hong Kong
|
|
|
|
|
The summit will consist of two panel discussions to highlight recent milestone achievements, our competitive advantages, and key business opportunities of the life and health sciences landscape in Hong Kong. For Panel Discussion 1: Driving innovation in healthcare system in Hong Kong, it will be joined by:
|
- Prof Philip Chiu, Director, Multi-scale Medical Robotics Center; Associate Dean (External Affairs), Faculty of Medicine; Professor and Chief of Upper GI and Metabolic Surgery, The Chinese University of Hong Kong
- Dr Gina Jiang, Managing Director, Hong Kong Institute of Biotechnology
- Dr Lo Su-vui, Chief Executive Officer, Hong Kong Genome Institute
- Dr Kenneth Tsang, Chief Executive Officer, Gleneagles Hospital Hong Kong, and
- Mr Falcon Chan, Partner, Strategy, Analytics and M&A, Deloitte China to be the moderator
|
|
|
|
|
|
|
Prof Philip Chiu
|
|
The Chinese University of Hong Kong
|
|
|
|
|
Dr Gina Jiang
|
|
The Hong Kong Institute of Biotechnology Limited
|
|
|
|
|
Dr Lo Su-vui
|
|
Hong Kong Genome Institute
|
|
|
|
|
|
|
Dr Kenneth Tsang
|
|
Gleneagles Hospital Hong Kong
|
|
|
|
|
Mr Falcon Chan
|
|
Deloitte China
|
|
Moderator
|
|
|
|
|
For Panel Discussion 2: Hong Kong as a life and health technology innovation hub, which talks about our "software" and "hardware" supports to enhance our biotech ecosystem. This panel discussion will be joined by:
|
- Ir Eric Chan, Chief Public Mission Officer, Hong Kong Cyberport Management Co. Ltd.
- Ms Jennifer Che, Managing Director, Eagle IP Limited
- Dr Grace Lau, Head of Institute for Translational Research, Hong Kong Science and Technology Parks Corporation
- Ms Simone Song, Founder & Senior Partner, ORI Capital
- Mr Henry Yau, Managing Director, HKU Clinical Trials Centre; CEO, HKU Clinical Trials Centre (China); Honorary Assistant Professor, Macau University of Science and Technology, and
- Dr Josephine Au, Senior Manager of Advanced Therapeutics, InvestHK to be the moderator
|
|
|
|
|
|
|
Ir Eric Chan
|
|
Hong Kong Cyberport Management Co. Ltd.
|
|
|
|
|
Ms Jennifer Che
|
|
Eagle IP Limited
|
|
|
|
|
Dr Grace Lau
|
|
Hong Kong Science and Technology Parks Corporation
|
|
|
|
|
|
|
Ms Simone Song
|
|
ORI Capital
|
|
|
|
|
Mr Henry Yau
|
|
HKU Clinical Trials Centre
|
|
|
|
|
Dr Josephine Au
|
|
Invest Hong Kong
|
|
Moderator
|
|
|
|
|
Best Regards,
Invest Hong Kong
|
|
|
|
|
